{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:56:52Z","timestamp":1792699012164,"version":"4.5.0"},"reference-count":18,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2021,11,10]]},"DOI":"10.1253\/circrep.cr-21-0115","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T22:21:34Z","timestamp":1634250094000},"page":"660-665","source":"Crossref","is-referenced-by-count":10,"title":["Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1253","volume":"3","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Oshima","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Narang","sequence":"additional","affiliation":[{"name":"Advocate Christ Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). <i>Hypertens Res<\/i> 2019; 42: 1235\u20131481.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circ Heart Fail<\/i> 2014; 7: 573\u2013579.","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. <i>Eur J Heart Fail<\/i> 2021; 23: 352\u2013380.","DOI":"10.1002\/ejhf.2115"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; on behalf of the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. <i>Circ J<\/i> 2021; 85: 1590\u20131689.","DOI":"10.1253\/circj.CJ-20-0910"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2006; 355: 251\u2013259.","DOI":"10.1056\/NEJMoa052256"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wan N, Rahman A, Nishiyama A. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. <i>J Hum Hypertens<\/i> 2021; 35: 148\u2013156.","DOI":"10.1038\/s41371-020-0377-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med<\/i> 1999; 341: 709\u2013717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med<\/i> 2011; 364: 11\u201321.","DOI":"10.1056\/NEJMoa1009492"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>N Engl J Med<\/i> 2003; 348: 1309\u20131321.","DOI":"10.1056\/NEJMoa030207"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rahman A, Sawano T, Sen A, Hossain A, Jahan N, Kobara H, et al. Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in Dahl salt-sensitive hypertensive rats. <i>Int J Mol Sci<\/i> 2021; 22: 2069.","DOI":"10.3390\/ijms22042069"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of Type 2 diabetes with microalbuminuria: A randomized, double-blind, placebo-controlled, Phase II trial. <i>Clin J Am Soc Nephrol<\/i> 2019; 14: 1161\u20131172.","DOI":"10.2215\/CJN.14751218"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with Type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. <i>Clin J Am Soc Nephrol<\/i> 2020; 15: 1715\u20131727.","DOI":"10.2215\/CJN.06870520"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>Circ Heart Fail<\/i> 2014; 7: 51\u201358.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Oshima A, Imamura T, Narang N, Kinugawa K. Renoprotective effect of the mineralocorticoid receptor antagonist esaxerenone. <i>Circ Rep<\/i> 2021; 3: 333\u2013337.","DOI":"10.1253\/circrep.CR-21-0024"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Naruke T, Maemura K, Oki T, Yazaki M, Fujita T, Ikeda Y, et al. Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. <i>Hypertens Res<\/i> 2021; 44: 601\u2013603.","DOI":"10.1038\/s41440-020-00606-w"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Udelson JE. Heart failure with preserved ejection fraction. <i>Circulation<\/i> 2011; 124: e540\u2013e543.","DOI":"10.1161\/CIRCULATIONAHA.111.071696"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2019; 381: 1609\u20131620.","DOI":"10.1056\/NEJMoa1908655"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/11\/3_CR-21-0115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T03:35:07Z","timestamp":1636774507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/11\/3_CR-21-0115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-21-0115","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"article-number":"CR-21-0115"}}